![[ Back to EurekAlert! ]](http://www.eurekalert.org/images/back2e.gif){kind=small}
Public release date: 9-Apr-2013[ | E-mail |
Share ] Contact: Mary Leach
Mary_Leach@meei.harvard.edu
617-573-4170
Massachusetts Eye and Ear Infirmary
Research online, to be published in the May 2013 issue of American Journal of Pathology
BOSTON (April 9, 2013) Proliferative vitreoretinopathy (PVR), or the formation of scar tissue in the eye, is a serious, sight-threatening complication in people recovering from surgical repair of retinal detachment. PVR is difficult to predict, lacks effective treatment options, and substantially reduces an individual's quality of life. Each year 55,000 people are at risk for developing PVR in the United States alone.
A new study carried out by scientists from The Schepens Eye Research Institute/Massachusetts Eye and Ear and the Department of Ophthalmology, Harvard Medical School, and published on The American Journal of Pathology website and scheduled for the May 2013 print edition, suggests that Ranibizumab, an anti-VEGF-A monoclonal antibody fragment, is a potential prophylaxis for PVR.
"In this manuscript we present basic studies that have clear implications for disease pathogenesis and therapy," said senior author Andrius Kazlauskas, Ph.D, Senior Scientist and Sinon Scholar in Retinal Research, Mass. Eye and Ear/Schepens Eye Research Institute and Professor of Ophthalmology, Harvard Medical School.
Researchers found that the putative mediators of PVR pathogenesis are growth factors, which contribute to common diseases such as atherosclerosis and cancer. "Consequently, elucidating functional relationships between growth factors and resolving their contribution to pathogenesis is of wide interest because such information will substantially advance our ability to combat a broad spectrum of diseases," Dr. Kazlauskas said.
While investigating the functional relationships between growth factors known to promote pervasive human diseases, researchers discovered that Ranibizumab reduced the bioactivity of vitreous from patients and experimental animals with PVR, and protected rabbits from developing this disease.
These pre-clinical findings suggest that one of the clinically approved approaches to neutralize VEGF-A constitutes a novel prophylactic for an incurable, blinding disease.
"Our discoveries also raise the provocative idea that anti-VEGF-based therapies may be effective for managing more than the angiogenesis- and vascular-permeability-driven pathological conditions," Dr. Kazlauskas continues.
###
This study was funded by the NIH/National Eye Institute (EY022970), the Massachusetts Lions Foundation, the Department of Defense (WB1XWH-10-1-0392) and Canadian Institutes of Health Research (CIHR).
The full list of collaborators is available in the manuscript.
About Massachusetts Eye and Ear
Mass. Eye and Ear clinicians and scientists are driven by a mission to find cures for blindness, deafness and diseases of the head and neck. After uniting with Schepens Eye Research Institute in 2011, Mass. Eye and Ear in Boston became the world's largest vision and hearing research center, offering hope and healing to patients everywhere through discovery and innovation. Mass. Eye and Ear is a Harvard Medical School teaching hospital and trains future medical leaders in ophthalmology and otolaryngology, through residency as well as clinical and research fellowships. Internationally acclaimed since its founding in 1824, Mass. Eye and Ear employs full-time, board-certified physicians who offer high-quality and affordable specialty care that ranges from the routine to the very complex. U.S. News & World Report's "Best Hospitals Survey" has consistently ranked the Mass. Eye and Ear Departments of Otolaryngology and Ophthalmology as top five in the nation. Mass. Eye and Ear is home to the Ocular Genomics Institute which aims to translate the promise of personalized genomic medicine into clinical care.
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Public release date: 9-Apr-2013[ | E-mail |
Share ] Contact: Mary Leach
Mary_Leach@meei.harvard.edu
617-573-4170
Massachusetts Eye and Ear Infirmary
Research online, to be published in the May 2013 issue of American Journal of Pathology
BOSTON (April 9, 2013) Proliferative vitreoretinopathy (PVR), or the formation of scar tissue in the eye, is a serious, sight-threatening complication in people recovering from surgical repair of retinal detachment. PVR is difficult to predict, lacks effective treatment options, and substantially reduces an individual's quality of life. Each year 55,000 people are at risk for developing PVR in the United States alone.
A new study carried out by scientists from The Schepens Eye Research Institute/Massachusetts Eye and Ear and the Department of Ophthalmology, Harvard Medical School, and published on The American Journal of Pathology website and scheduled for the May 2013 print edition, suggests that Ranibizumab, an anti-VEGF-A monoclonal antibody fragment, is a potential prophylaxis for PVR.
"In this manuscript we present basic studies that have clear implications for disease pathogenesis and therapy," said senior author Andrius Kazlauskas, Ph.D, Senior Scientist and Sinon Scholar in Retinal Research, Mass. Eye and Ear/Schepens Eye Research Institute and Professor of Ophthalmology, Harvard Medical School.
Researchers found that the putative mediators of PVR pathogenesis are growth factors, which contribute to common diseases such as atherosclerosis and cancer. "Consequently, elucidating functional relationships between growth factors and resolving their contribution to pathogenesis is of wide interest because such information will substantially advance our ability to combat a broad spectrum of diseases," Dr. Kazlauskas said.
While investigating the functional relationships between growth factors known to promote pervasive human diseases, researchers discovered that Ranibizumab reduced the bioactivity of vitreous from patients and experimental animals with PVR, and protected rabbits from developing this disease.
These pre-clinical findings suggest that one of the clinically approved approaches to neutralize VEGF-A constitutes a novel prophylactic for an incurable, blinding disease.
"Our discoveries also raise the provocative idea that anti-VEGF-based therapies may be effective for managing more than the angiogenesis- and vascular-permeability-driven pathological conditions," Dr. Kazlauskas continues.
###
This study was funded by the NIH/National Eye Institute (EY022970), the Massachusetts Lions Foundation, the Department of Defense (WB1XWH-10-1-0392) and Canadian Institutes of Health Research (CIHR).
The full list of collaborators is available in the manuscript.
About Massachusetts Eye and Ear
Mass. Eye and Ear clinicians and scientists are driven by a mission to find cures for blindness, deafness and diseases of the head and neck. After uniting with Schepens Eye Research Institute in 2011, Mass. Eye and Ear in Boston became the world's largest vision and hearing research center, offering hope and healing to patients everywhere through discovery and innovation. Mass. Eye and Ear is a Harvard Medical School teaching hospital and trains future medical leaders in ophthalmology and otolaryngology, through residency as well as clinical and research fellowships. Internationally acclaimed since its founding in 1824, Mass. Eye and Ear employs full-time, board-certified physicians who offer high-quality and affordable specialty care that ranges from the routine to the very complex. U.S. News & World Report's "Best Hospitals Survey" has consistently ranked the Mass. Eye and Ear Departments of Otolaryngology and Ophthalmology as top five in the nation. Mass. Eye and Ear is home to the Ocular Genomics Institute which aims to translate the promise of personalized genomic medicine into clinical care.
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Source: http://www.eurekalert.org/pub_releases/2013-04/meae-rmp040413.php
yamaguchi road house occupy oakland occupy oakland morgellons disease arik armstead sag awards red carpet
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.